Label Image (Lbl500907770)
Levetiracetam Tablet, Film Coated
Product Images NDC 50090-7770
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 50090-7770). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)
This text includes a figure showing the Responder Rate with a 250% reduction from baseline in Study 1. The data points in the figure range from 0% to 39.6%. The information indicates that the results are statistically significant versus placebo.*
Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)
This text provides a figure showing the Responder Rate (250% Reduction from Baseline) in Study 2, during Period A. The data includes percentages of responder rates for different groups, such as Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. It also indicates a statistically significant result for one of the groups compared to placebo.*
Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)
This text provides data on the Responder Rate (>50% Reduction from Baseline) in Study 3, comparing the results between Placebo (N=104) and Levetiracetam 3000 mg/day (N=180). The percentages of responders in each group are shown in a graphical format, with Levetiracetam 3000 mg/day demonstrating a statistically significant difference compared to Placebo.*
Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)
This text provides information about the Responder Rate (a 50% Reduction from Baseline) in Study 4 of a study comparing Placebo (N=97) and Levetiracetam (N=101). The results show that the responder rate was 44.6% for placebo and 45% for Levetiracetam. The text also indicates that Levetiracetam was statistically significant compared to placebo.*
Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)
This data from Figure 5 presents the Responder Rate for all patients aged 1 month to < 4 years, showing a >50% reduction from baseline in Study 5. The result indicates that Lovetracatam had a statistically significant effect compared to placebo, with a response rate of 190.6%.*
Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)
This text provides information on the Responder Rate (250% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7. It includes the percentages of patients responding to treatment with placebo and Levetiracetam, as well as noting a statistically significant difference in effectiveness compared to placebo.*
Chemical Structure (Levetiracetam Str)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
